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Abstract
Resistance to imatinib in patients with chronic myelogenous leukemia (CML) or Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has emerged as a significant clinical
issue. Dasatinib is a tyrosine kinase inhibitor that has 325-fold greater in vitro activity against native
BCR-ABL (breakpoint cluster region-Abelson leukemia virus) compared with imatinib and can
overcome primary (intrinsic) and secondary (acquired) imatinib resistance. Here, we review the
clinical profile of dasatinib in imatinib-resistant and -intolerant patients and share clinical
approaches for managing adverse events (AEs) to ensure maximum patient benefit. References
were obtained through literature searches on PubMed as well as from the Proceedings of Annual
Meetings of the American Society of Clinical Oncology, the American Society of Hematology, and
European Hematology Association. Phase II and III studies of dasatinib in patients with imatinib-
resistant or -intolerant CML in any phase or Ph+ ALL were selected for discussion. Dasatinib is
currently indicated for the treatment of patients with imatinib-resistant or -intolerant CML or Ph+
ALL. AEs associated with dasatinib are typically mild to moderate, and are usually resolved with
temporary treatment interruption and/or dose adjustments. A Phase III dose optimization study
showed that in patients with chronic phase (CP) CML, 100 mg once-daily dasatinib improves the
safety profile, particularly pleural effusion and thrombocytopenia, while maintaining efficacy
compared with the previously recommended dose of 70 mg twice-daily. Dasatinib has a manageable
safety profile. For patients with CP CML, a new recommended starting dose of 100 mg once daily
has recently been approved. The recommended dose for patients with advanced CML or Ph+ ALL
remains 70 mg twice daily.
Introduction
Chronic myelogenous leukemia (CML) is a myeloprolif-
erative disorder of blood stem cells [1]. It accounts for
approximately 15% of all leukemias diagnosed in adults
[2]. The causative molecular defect is the BCR-ABL pro-
tein, which is encoded by the Philadelphia chromosome
(Ph) [3]. This genetic aberration arises from an exchange
of genetic material between chromosomes 9 and 22,
which results in the fusion of the breakpoint cluster
region (BCR) and the Abelson leukemia virus (ABL)
genes. The resulting gene encodes a protein kinase that is
constitutively active and activates a number of proteins
involved in regulating the cell cycle. Cell division is accel-
erated and DNA repair is affected.
The median age of patients at the time of CML presenta-
tion is 53 years; however, the disease can affect patients of
all ages [1]. CML typically begins with a chronic phase
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and, over the course of 3 to 5 years, progresses from an
accelerated phase (AP) to a blast crisis (BC) or terminal
phase [1]. Approximately 85% of patients with CML are
diagnosed in the chronic phase and are usually asympto-
matic or have only mild symptoms [4]. Some of the crite-
ria used to define the accelerated phase are more than
20% basophils and 10% to 19% myeloblasts in the blood
or bone marrow, cytogenetic evolution with new abnor-
malities in addition to the Ph chromosome, and increased
white blood cell count unresponsive to therapy [4]. The
accelerated phase is significant because it signals that the
disease is progressing and that transformation to the blast
phase is imminent. The blast phase is most often the final
phase of CML, behaving like acute leukemia, with rapid
progression and short survival of the patients. Character-
istics include more than 20% myeloblasts or lymphob-
lasts in the blood or bone marrow, large clusters of blasts
in the bone marrow on biopsy, and development of a
solid focus of leukemia outside the bone marrow [4,5].
Ph is also the most common genetic abnormality in adult
acute lymphocytic leukemia (ALL); approximately 25% of
adult cases are Ph+ [6,7]. Furthermore, the incidence of
Ph+ ALL increases with age, accounting for an estimated
50% of ALL cases in patients older than 50 years [6,7].
Patients with Ph+ ALL progress rapidly and are at high risk
of developing central nervous system leukemia [8], high-
lighting the need for improved treatments.
The identification of the BCR-ABL kinase fusion protein
and its role in the pathogenesis of CML has led to the
emergence of BCR-ABL-targeted therapy, which has
become the standard of care for patients with CML. His-
torically, patients with CML were treated with agents such
as hydroxyurea, cytarabine, and alfa-interferon. Although
hydroxyurea improves outcomes compared with previous
chemotherapies, it has a transient effect and was super-
seded by the use of alfa-interferon and, subsequently,
combinations of chemotherapy and alfa-interferon [9].
Alfa-interferon treatment significantly prolongs survival
but is confounded by associated toxicities [9]. Allogeneic
stem cell transplantation following high-dose chemother-
apy is a potentially curative treatment for patients with
chronic phase CML (CP CML) [1]. However, the success of
this procedure is significantly lower in patients older than
40 years because of the procedure's toxicity. Other varia-
bles may also influence outcome, such as disease stage
and level of donor-recipient human leukocyte antigen
(HLA) matching [1].
The emergence of BCR-ABL-targeted agents has revolu-
tionized the treatment of CML. These agents compete with
adenosine triphosphate (ATP) for its binding pocket on
the BCR-ABL protein, preventing the functioning of the
BCR-ABL enzyme and ultimately killing the cell. In 2001,
imatinib became available and was the first BCR-ABL-tar-
geted agent indicated for the treatment of CML; a determi-
nation based on the Phase III International Randomized
Study of Interferon versus STI571 (IRIS clinical trial) (Fig-
ure 1). In this study, imatinib induced greater response
rates, improved freedom from progression to AP or BC,
and was better tolerated compared with alfa-interferon
plus cytarabine [10]. Imatinib has since become the
standard first-line therapy for patients with CP CML and
is indicated for the treatment of patients with AP or BC
CML [11].
Despite the significant improvements in the outcome for
patients with CML treated with imatinib [12], resistance
to this agent has emerged as a significant clinical issue
[13]. Results from a Phase III randomized study have
demonstrated that a number of patients have primary or
acquired resistance to imatinib treatment [14,15]. In this
study, primary resistance developed in an estimated 5% of
patients with newly diagnosed CP CML who failed to
achieve a complete hematologic response (CHR) with
imatinib at 3 months. A further 16% who failed to achieve
a major cytogenetic response (MCyR) with imatinib at 12
months, and 24% who failed to achieve a complete
cytogenetic response (CCyR) at 18 months [14-16].
Relapse in patients receiving imatinib occurred in approx-
imately 17% of patients over 5 years, and 7% of patients
developed disease progression after the same period of
time [14]. Resistance to imatinib is more common in
Chemical structures of imatinib (C29H31N7O) and dasatinib  (C22H26C1N7O2S) Figure 1
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patients who are in advanced stages of CML, and relapse
occurs in the majority of these patients who initially
respond to treatment [17-19]. In a single-center study of
patients with BCR-ABL-positive leukemias, the percent-
ages of patients in CP, AP, or blast phase (BP) CML with
imatinib resistance were 29%, 45%, and 92%, respectively
[18].
Although most imatinib-related adverse events (AEs) gen-
erally resolve with dose modifications or interruptions,
intolerance is a concern in patients treated with imatinib.
After a median follow-up of 4.5 years, 5% of patients in
the IRIS trial discontinued imatinib as a result of AEs [20].
Grade 3 or 4 AEs reported in this study included neutro-
penia, thrombocytopenia, anemia, and elevated liver
enzymes [20].
Currently, there are several treatment options available for
the second-line treatment of CML. Increasing the dose of
imatinib (600–800 mg/day) is one option for treating
patients who are resistant to standard doses (400 mg/
day). Studies have shown that 35% to 40% of patients
with CML who did not respond with standard-dose imat-
inib subsequently achieved an MCyR with high-dose
imatinib [21,22]. However, these responses were short-
lived with most patients relapsing within 2 to 11 months.
Use of new and more potent tyrosine kinase inhibitors
can be a second option; two other BCR-ABL inhibitors are
now available for the treatment of patients with imatinib
resistance or intolerance. Nilotinib, was introduced in
November, 2007 for the treatment of patients with CP or
AP CML who are resistant to or intolerant of imatinib.
Dasatinib is indicated for the treatment of patients with
imatinib-resistant or -intolerant CML in any phase or Ph+
ALL. In this article, we review the clinical profile of dasat-
inib in imatinib-resistant and -intolerant patients, discuss
the newly approved dose for patients with CP CML, and
share clinical approaches in managing AEs to ensure max-
imum patient benefit.
Dasatinib
Dasatinib is a thiazole carboximide agent with potent
activity against the BCR-ABL kinase fusion protein and the
v-src sarcoma viral oncogene homolog (SRC) family
kinases (SFKs) (Figure 1) [23]. Dasatinib also has activity
against other oncogenic tyrosine kinases, such as c-Kit,
platelet-derived growth factor-receptor (PDGFR), and
ephrin-A receptor [23-26]. In vitro, dasatinib demon-
strated 325-fold greater activity against native BCR-ABL
compared with imatinib [27,28].
Treatment with dasatinib can overcome BCR-ABL-
dependent and -independent mechanisms of resistance to
imatinib. Because of the greater potency of dasatinib
against native BCR-ABL, dasatinib may have activity in
patients with imatinib resistance caused by BCR-ABL over-
expression [29,30]. Dasatinib can also overcome mecha-
nisms of resistance caused by BCR-ABL kinase mutations
and has demonstrated activity against the majority of
known imatinib-resistant mutations except T315I, and
had shown relative insensitivity to F317l [27,28,31].
BCR-ABL-independent imatinib resistance may develop
as a result of activation of alternative signaling pathways.
In vitro studies using SRC kinase inhibitors reveal that
SFKs play an active role in BCR-ABL signal transduction
and have demonstrated that inhibition of SFKs results in
growth arrest and induction of apoptosis in Ph+ CML cell
lines [32]. Furthermore, one SFK, LYN, was highly overex-
pressed and activated in bone marrow cell lines estab-
lished from patients with resistance to imatinib.
Inhibition of LYN reduced proliferation and survival of
these imatinib-resistant cell lines compared with the non-
resistant parental cell population, implicating SFK activa-
tion in some instances of imatinib resistance [33]. The
inhibition of SFKs by dasatinib may contribute to the effi-
cacy of this agent in BCR-ABL-independent imatinib
resistance, helping to improve overall outcome. In the
United States and Europe, dasatinib is the first and only
dual SFK/BCR-ABL inhibitor indicated for the treatment
of imatinib-resistant and imatinib-intolerant patients in
all phases of CML or with Ph+ ALL.
Dosage and administration
Dasatinib was initially indicated for patients with CML in
any phase or with Ph+ ALL at a starting dose of 70 mg
twice daily. This dose was chosen based on Phase I study
data. However, similar efficacy was noted with doses of
100 mg/day or greater, irrespective of the schedule of
administration [34]. As a result, a dose optimization study
(CA180-034) was launched, and results from this study
eventually led to a change in the recommended starting
dose for patients with CP CML at100 mg administered
orally once daily, either in the morning or in the evening.
For patients with AP CML, myeloid BP CML, lymphoid BP
CML, or Ph+ ALL, the recommended starting dose
remains 70 mg twice daily. Dose modifications may be
warranted, depending on tolerability or level of response
to dasatinib.
Dasatinib is supplied as white to off-white, film-coated,
biconvex tablets (20, 50, and 70 mg) to be stored at room
temperature. To minimize the risks of medication error, it
is also necessary to caution patients that varying doses of
dasatinib are each available in the same color tablets. This
is specifically warranted if dose adjustments are required
where more than one dose strength of the tablets are
needed to deliver the appropriate dose. A patient diary is
highly recommended to encourage patient compliance.
Tablets should not be crushed or cut, but should be swal-Journal of Hematology & Oncology 2009, 2:10 http://www.jhoonline.org/content/2/1/10
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lowed whole, and can be taken with or without food. If
vomiting occurs within 30 minutes after dosing, repeat
dosing should be considered.
Pharmacokinetics
Pharmacokinetic analysis has demonstrated that dasat-
inib is rapidly absorbed and exhibits linear elimination
characteristics. Dasatinib Cmax occurs between 0.5 and 6
hours following administration, and the overall mean ter-
minal half-life is 3 to 5 hours [35]. The cause of the varia-
bility in Cmax has not yet been determined; however, it is
likely due to the result of inherent differences between the
patients studied. The low bioavailability of dasatinib can-
not be attributed to P-glycoprotein activity, as dasatinib is
not a substrate for this drug transporter [36]. No clinically
relevant effects on absorption have been observed from
food consumption. In preclinical models, the oral bioa-
vailability of dasatinib ranged from 14% to 34%. In
patients, the total volume of distribution of dasatinib is
2505 L, implying that dasatinib is well distributed in
extravascular space [35].
The metabolism of dasatinib is mainly hepatic, and the
CYP3A4 enzyme is primarily responsible for the forma-
tion of active metabolites [35]. The FMO-3 enzyme and
UGT enzymes are also involved in the formation of dasat-
inib metabolites. The active metabolites of dasatinib have
been identified as hydroxylated metabolites (M20 and
M24), an N-dealkylated metabolite (M4), an N-oxide
metabolite (M5), an acid metabolite (M6), and the glu-
curonide conjugates (M8a, b) [37]. These metabolites are
unlikely to play a major role in the observed pharmacol-
ogy of the drug, as they were found to represent only
about 5% of the area under the plasma drug concentra-
tion-time curve (AUC). Dasatinib is primarily excreted as
metabolites (85%) in the feces [37].
There are no clinically relevant effects of age and gender
on the pharmacokinetics of dasatinib, although dasatinib
has not been evaluated in pediatric patients and is there-
fore not recommended as a treatment option for this
patient population. There are currently no clinical studies
conducted in patients with impaired liver or renal func-
tion. The metabolism of dasatinib is mainly hepatic via
oxidative biotransformation; therefore, caution is recom-
mended in patients with hepatic impairment. The per-
centage of dasatinib and its metabolites that is excreted via
the kidney is less than 4% [35,37].
Drug interactions
Dasatinib is a CYP3A4 substrate. Studies have shown that
the AUC and/or Cmax of dasatinib are altered when coad-
ministered with ketoconazole (a CYP3A4 inhibitor), sim-
vastatin (a CYP3A4 substrate/inhibitor) or rifampin (a
CYP3A4 inducer) [38]. Therefore, use of CYP3A4 sub-
strates/inhibitors during dasatinib treatment should be
avoided if possible, as this may increase bioavailability of
dasatinib. If use of CYP3A4 inhibitors cannot be avoided,
patients should be monitored closely for dasatinib toxic-
ity and reduction of the dose by 20 to 40 mg per day
should be considered. CYP3A4 inducers may decrease
dasatinib plasma concentrations. In patients who require
CYP3A4 inducers, alternate agents with less enzyme
induction potential should be used if possible. If the use
of a CYP3A4 inducer is necessary, dasatinib dose escala-
tion in 20 mg increments is recommended. St. John's
wort, a CYP3A4 inducer, may also decrease dasatinib
plasma concentrations and should not be taken by
patients receiving dasatinib (Additional file 1, Table S1)
[11,35,39].
Preclinical data have shown that the solubility of dasat-
inib is pH-dependent, which suggests that concomitant
administration of antacids could decrease the absorption
of dasatinib. In a clinical study evaluating the pharmacok-
inetics of dasatinib, a 55% decrease in AUC was observed
when dasatinib was administered simultaneously with
antacids. However, no decrease in AUC was reported
when antacids were administered 2 hours prior to dasat-
inib [39]; therefore, antacids should be taken at least 2
hours before or after dasatinib administration. The use of
proton pump inhibitors and histamine-2 (H2) blockers
should be avoided, because such use is likely to decrease
the bioavailability of dasatinib for up to 10 hours. The use
of antacids in place of proton pump inhibitors or H2
blockers is recommended [11,35].
Initial in vitro study data suggested that dasatinib has the
potential to prolong cardiac ventricular repolarization
(QT interval). In single-arm clinical studies, 3 patients (<
1%) experienced a QTcF > 500 msec. Dasatinib should
therefore be administered with caution in patients with a
history of QT prolongation, electrolyte imbalance (potas-
sium and magnesium), congenital long QT syndrome, or
those receiving concurrent anti-arrhythmic medications,
or other medications that can lead to QT prolongation
(Additional file 1, Table S1) [35].
Special populations
Dasatinib use should be avoided in women who are preg-
nant or considering becoming pregnant. Patients who use
dasatinib while pregnant or who become pregnant during
dasatinib use should be informed of the potential toxicity
to the fetus. Women should not breast-feed while taking
dasatinib, because it is unknown whether dasatinib is
excreted in human milk [35].
A recently reported set of case studies from clinical trials
and post-marketing reports evaluated a small number of
patients (8 male and 8 female) who had either conceivedJournal of Hematology & Oncology 2009, 2:10 http://www.jhoonline.org/content/2/1/10
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or had a partner conceive whilst receiving dasatinib [40].
Of the eight females who became pregnant whilst receiv-
ing dasatinib, there were three cases of induced abortion
(two due to patient decision, one for unknown reasons),
two cases of spontaneous abortion (one at 8 weeks in a
38-year-old patient [G1P1], one at 9 weeks gestation in a
33-year-old [G3P3]) and three deliveries (one normal,
one by caesarean and one unknown). Of the eight males
with pregnant partners, seven normal newborns were
reported, and one case of unknown outcome. The authors
concluded that dasatinib treatment does not have a nega-
tive impact on pregnancy (for mother or fetus); however,
patients receiving dasatinib should be advised to practice
adequate contraception.
A larger study evaluated the effect of imatinib on 180
women, with outcomes data available for 125 patients
[41]. In total, 50% delivered normal infants, 28% under-
went induced abortions (3 due to abnormalities). Abnor-
malities were identified in 12 infants, with 3 having
strikingly similar complex malformations. The authors
noted that this was a cause for concern, concluding that
whilst most pregnancies have a successful outcome, there
appears to be a risk that imatinib exposure may cause mal-
formation.
In clinical studies, no differences in the safety and efficacy
of dasatinib were reported between the 23% (119/511) of
patients who were older than 65 years and those who were
younger (18–65 years). However, it remains possible that
some elderly patients may have greater sensitivity to
dasatinib. The safety and efficacy of dasatinib have not
been established in patients younger than 18 years [35].
Clinical studies
The phase II START program
Dasatinib has shown efficacy in a series of multicenter,
open-label Phase II clinical studies with patients in all
phases of CML or with Ph+ ALL who are resistant to or
intolerant of imatinib (the START [SRC/Abl Tyrosine
kinase inhibition Activity: Research Trials of dasatinib]
program). Hematologic and cytogenetic responses were
achieved in patients in all phases of CML and in patients
with Ph+ ALL (Additional file 1, Table S2) [42-49]. The
responses observed in these studies were durable; among
patients with CP CML who achieved a MCyR in the Phase
II START C trial, 88% had maintained their response at
24-months follow-up [50]. Furthermore, responses were
achieved across all BCR-ABL mutations, except T315I.
These studies led to the approval of dasatinib for these
patients [42-44].
START-R was a randomized, comparative trial of dasatinib
70 mg twice daily versus high-dose imatinib (800 mg) in
patients with imatinib-resistant CP CML [49]. Patients
receiving dasatinib had a significantly greater rate of
hematologic and cytogenetic responses than patients
receiving high-dose imatinib (Additional file 1, Table S2).
Dasatinib was also superior to high-dose imatinib with
regard to progression-free survival (PFS) (hazard ratio:
0.14; P < .001).
Phase III dose optimization studies
Although dasatinib 70 mg twice daily was the chosen dose
in the Phase II START program, a Phase I study showed
similar efficacy between once-daily and twice-daily treat-
ment schedules, with significant hematologic and cytoge-
netic responses achieved with both regimens [34]. Long-
term follow-up of this Phase I study showed that pleural
effusions were less frequent with a once-daily schedule
than with twice-daily dosing [51]. In addition, as a result
of dose reductions, the median total daily dose across the
Phase II program in patients with CP CML was close to
100 mg/day [43,48]. In light of these findings, two open-
label, Phase III trials have been conducted to evaluate the
optimal dosing regimen of dasatinib in CML and Ph+
ALL.
In the CA180-034 study [44,52], patients with CP CML
who were resistant to or intolerant of imatinib (N = 662)
were randomized to dasatinib 100 mg once daily, 50 mg
twice daily, 140 mg once daily, or 70 mg twice daily.
Marked and similar hematologic and cytogenetic efficacy
was seen across all four dasatinib arms in the CA180-034
trial. However, there was a difference in safety profiles.
Dasatinib 100 mg once daily was associated with a
reduced incidence of cytopenia and pleural effusions
compared with the 70 mg twice-daily arm and with the
lowest incidence of treatment interruption and discontin-
uation compared with all the other arms. The rate of dis-
continuation due to toxicity was lower compared with 70
mg twice daily (6% vs 15%), suggesting that once-daily
dasatinib is better tolerated than a twice-daily schedule.
The rates of treatment interruption and dose reduction for
any reason were also lower with 100 mg dasatinib once
daily compared with 70 mg twice daily (58% vs 71% and
33% vs 57%, respectively). The results of this study dem-
onstrate that a 100 mg once-daily dose of dasatinib offers
the most favorable overall benefit/risk assessment in CP
CML, and have prompted a change in the recommended
starting dose of dasatinib to this regimen [35]. It should
be noted that the recommended starting dose remains 70
mg twice daily for patients with advanced phase disease
[35].
Adverse events and management recommendations
The most common drug-related serious toxicities in dasat-
inib clinical trials were fluid retention (8%), pleural effu-
sion (5%), diarrhea (3%), skin rash (1%), headache
(1%), hemorrhage (6%), fatigue (2%), nausea (1%), andJournal of Hematology & Oncology 2009, 2:10 http://www.jhoonline.org/content/2/1/10
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dyspnea (4%). Discontinuation rates as a result of toxici-
ties were 9%, 10%, 15%, and 8% for patients with CP, AP,
and BP CML, and Ph+ ALL, respectively [35]. Grade 3/4
dasatinib-related AEs were generally comparable in all
phases of CML. However, fluid retention/pleural effusion,
hemorrhage, and febrile neutropenia were of greater fre-
quency in advanced CML [42-49]. Of particular note was
the lack of cross-intolerance with imatinib; there was no
recurrence of AEs associated with imatinib intolerance.
Imatinib intolerance was defined as the occurrence of at
least a grade 3 nonhematologic or grade 4 hematologic
toxicity that persisted for more than 7 days as a result of
imatinib therapy [44]. Furthermore, the tolerability pro-
file of dasatinib was comparable between imatinib-resist-
ant and -intolerant patients [42].
As cytopenias (eg, neutropenia and thrombocytopenia)
and fluid retention are commonly associated with dasat-
inib treatment, patients should be monitored closely for
these AEs. Complete blood counts should be performed
weekly for the detection of cytopenias, especially during
the first two months following initiation of therapy.
Adjustment of the dose of dasatinib may be advisable in
order to manage cytopenias (Additional file 1, Table S3)
[35]. Doses can be reduced from 140 to 100 mg/day or
from 100 to 80 mg/day to allow continuation of dasatinib
treatment. Patients with advanced phase disease may have
disease-related cytopenias. Therefore, treatment discon-
tinuation or interruption is not recommended due to the
poor prognosis of these patients [11]. Myeloid growth fac-
tors and/or platelet transfusions may help to lessen the
risks of complications associated with neutropenia and
thrombocytopenia, respectively, and reduce the need for
dose modification [11,53,54].
Patients should be monitored closely for the signs and
symptoms of fluid retention, such as pitting edema, short-
ness of breath, and rapid weight gain. Patients exhibiting
these symptoms should undergo radiographic studies to
promptly detect pleural effusions. Fluid retention can be
effectively managed with supportive care (diuretics, ster-
oids) and dose interruption [11,55]. In severe cases of
fluid retention, the drug should be held until symptoms
improve to grade 1 or better (mild or asymptomatic), and
then the dose of dasatinib should be reduced from 140 to
100 mg/day or from 100 to 80 mg/day. In clinical trials,
early identification, temporary interruption of treatment,
diuretic and/or pulse steroid usage, and subsequent dasat-
inib dose reduction led to resolution of adverse event-
related symptoms in all cases [49,56].
QT prolongation is a rare but severe AE that should be
monitored during dasatinib therapy. All patients should
be screened for risks of QT prolongation such as hypoka-
lemia, hypomagnesemia, congenital long QT syndrome,
and concurrent mediations that can lead to QT prolonga-
tion (Additional file 1, Table S1). All electrolyte abnor-
malities should be corrected prior to initiation of
dasatinib. Other grade 3/4 laboratory abnormalities such
as hypocalcemia and hypophosphatemia have been
reported with dasatinib [35].
In clinical studies, the majority of nonhematologic AEs
were mild to moderate (grades 1/2) in severity and
resolved spontaneously without the need for dose modi-
fication. Interventions for managing grade 3 nonhemato-
logic AEs are shown in Additional file 1, Table S4 [11]. For
grade 3 nonhematologic AEs that do not respond to
symptomatic measures, dasatinib should be withheld
until the AE resolves to grade 1 or better (asymptomatic).
Dasatinib treatment can then be resumed, and lower
doses should be considered [11].
Summary
Dasatinib represents a promising treatment option for
patients in all phases of CML and for patients with Ph+
ALL for whom treatment with imatinib has failed. Resist-
ance to imatinib is a significant clinical issue in the treat-
ment of CML and Ph+ ALL; however, treatment with
dasatinib can overcome intrinsic or acquired resistance to
imatinib.
In clinical trials, hematologic and cytogenetic responses to
dasatinib were durable and were achieved in patients in
all phases of CML as well as in patients with Ph+ ALL [42-
49]. Compared with high-dose imatinib (800 mg), dasat-
inib 70 mg twice daily demonstrated a significantly
greater rate of hematologic and cytogenetic responses in
patients with imatinib-resistant CP CML [49]. A Phase III
dose optimization study revealed that the safety profile of
dasatinib was improved and efficacy maintained when
dasatinib was administered to patients with CP CML on a
100 mg once-daily schedule [44]. Furthermore, while
acknowledging the potential safety benefits of dasatinib
140 mg once daily, another Phase III trial demonstrated
that dasatinib 70 mg administered twice daily to patients
with advanced CML or Ph+ ALL resulted in a more dura-
ble response and longer PFS compared with once-daily
dosing [57].
AEs associated with dasatinib treatment are typically mild
to moderate, and most can be resolved with temporary
withdrawal of dasatinib and/or dose adjustments.
Patients should be monitored for AEs commonly associ-
ated with dasatinib, such as cytopenias and fluid reten-
tion. Adjusting the dose of dasatinib from 140 to 100 mg/
day or from 100 to 80 mg/day may allow continuation of
dasatinib in some cases.Journal of Hematology & Oncology 2009, 2:10 http://www.jhoonline.org/content/2/1/10
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In patients with CP CML, dasatinib 100 mg once daily
improves the safety profile and compliance while main-
taining efficacy compared with the 70 mg twice-daily
schedule. Because of these findings, 100 mg dasatinib
once daily is now approved for patients with CP CML. In
patients with AP CML, BP CML, or Ph+ ALL, the recom-
mended dose remains 70 mg dasatinib administered
twice daily.
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